Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
Total Valuation
ALX Oncology Holdings has a market cap or net worth of $78.62M. The enterprise value is -$40.95M.
Market Cap$78.62M
Enterprise Value-$40.95M
Share Statistics
ALX Oncology Holdings has 54,218,002 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,218,002
Owned by Insiders2.95%
Owned by Institutions31.79%
Financial Efficiency
ALX Oncology Holdings’s return on equity (ROE) is -1.19 and return on invested capital (ROIC) is -108.24%.
Return on Equity (ROE)-1.19
Return on Assets (ROA)-0.91
Return on Invested Capital (ROIC)-108.24%
Return on Capital Employed (ROCE)-1.10
Revenue Per Employee0.00
Profits Per Employee-2.07M
Employee Count65
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ALX Oncology Holdings is ―. ALX Oncology Holdings’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.77
Price to Fair Value0.77
Price to FCF-0.71
Price to Operating Cash Flow-0.66
PEG Ratio0.02
Income Statement
In the last 12 months, ALX Oncology Holdings had revenue of 0.00 and earned -134.85M in profits. Earnings per share was -2.58.
Revenue0.00
Gross Profit-872.00K
Operating Income-142.47M
Pretax Income-134.85M
Net Income-134.85M
EBITDA-132.25M
Earnings Per Share (EPS)-2.58
Cash Flow
In the last 12 months, operating cash flow was -97.21M and capital expenditures -223.00K, giving a free cash flow of -97.43M billion.
Operating Cash Flow-97.21M
Free Cash Flow-97.43M
Free Cash Flow per Share-1.80
Dividends & Yields
ALX Oncology Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.41
52-Week Price Change-22.46%
50-Day Moving Average1.48
200-Day Moving Average0.94
Relative Strength Index (RSI)50.89
Average Volume (3m)670.12K
Important Dates
ALX Oncology Holdings upcoming earnings date is Mar 5, 2026, After Close (Confirmed).
Last Earnings DateNov 7, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
ALX Oncology Holdings as a current ratio of 7.26, with Debt / Equity ratio of 25.12%
Current Ratio7.26
Quick Ratio7.26
Debt to Market Cap0.11
Net Debt to EBITDA<0.01
Interest Coverage Ratio-82.40
Taxes
In the past 12 months, ALX Oncology Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ALX Oncology Holdings EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.71.
EV to Sales0.00
EV to EBITDA-0.65
EV to Free Cash Flow-0.71
EV to Operating Cash Flow-0.71
Balance Sheet
ALX Oncology Holdings has $60.63M in cash and marketable securities with $4.35M in debt, giving a net cash position of $56.28M billion.
Cash & Marketable Securities$60.63M
Total Debt$4.35M
Net Cash$56.28M
Net Cash Per Share$1.04
Tangible Book Value Per Share$2.18
Margins
Gross margin is -22.12%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-22.12%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ALX Oncology Holdings is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside106.90% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast31.98%